Living dossier · Competitive landscape

Amyloid-beta in Alzheimer's disease

Primary identifiers: 7
Sponsors tracked: 4
Evidence types: 2 of 3
Last refreshed: 2026-07-28 · monthly

MightyRayn panel synthesis

OmniRayn’s reading of this landscape — our interpretation, not a registry fact

Amyloid removal has become an engineering problem rather than a hypothesis, and the registry reads accordingly: the active studies are about dosing schedule, geography and prevention rather than whether clearance happens. The most useful item is a model-based meta-analysis across three antibodies showing that ARIA-E incidence tracks the RATE of plaque removal rather than exposure alone — which reframes the safety signal as a dial on the same mechanism that produces the benefit, not an unrelated toxicity. That is why a dedicated trial here studies dosing regimen against ARIA-E, and it is the constraint any new entrant inherits. Read alongside our tau landscape: the same platform trial shows plaque clearance leaves tangle biomarkers untouched.

Programs and primary evidence

Sponsor	Asset	Phase	Mechanism	Primary source
Eli Lilly and Company	Donanemab (TRAILBLAZER)	3	anti-amyloid-beta monoclonal antibody	NCT05508789 — Global Phase 3 of donanemab in early symptomatic Alzheimer's disease
Eli Lilly and Company	Donanemab dosing regimens	3	dosing schedule as a lever on ARIA-E and amyloid lowering	NCT05738486 — Effect of different donanemab dosing regimens on ARIA-E and amyloid lowering in early symptomatic disease
Eli Lilly and Company	Donanemab (China)	3	anti-amyloid-beta monoclonal antibody	NCT07571161 — Donanemab versus placebo in Chinese participants at risk of cognitive and functional decline
Washington University School of Medicine	Remternetug (DIAN-TU primary prevention)	2/3	anti-amyloid antibody in primary prevention	NCT05552157 — Platform trial for primary prevention of disease progression in dominantly inherited Alzheimer's disease
Washington University School of Medicine	Gantenerumab / solanezumab (DIAN-TU)	2/3	anti-amyloid antibodies with biomarker and cognitive endpoints	NCT01760005 — Long-running platform trial of disease-modifying therapies in dominantly inherited Alzheimer's disease
University of Miami (Baumel)	Mesenchymal stem cells added to anti-amyloid mAbs	2	adjunct to anti-amyloid monoclonal antibody therapy	NCT07512362 — Pilot of a single hMSC infusion in patients treated with anti-amyloid monoclonal antibodies
AbbVie	model-based meta-analysis (not a preclinical study)	—	exposure-response linking plaque-removal rate to ARIA-E hazard	10.1002/psp4.70038 — Model-based meta-analysis across aducanumab, lecanemab and donanemab: ARIA-E incidence rate depends on the RATE of amyloid plaque removal, with a drug-dependent scaling factor

Method and limits

Programs are enumerated from primary registries (ClinicalTrials.gov, PubMed). A program appears here only if a primary record links this target to this indication as a therapeutic hypothesis — associations and risk markers are excluded by design.
Every claim above carries the identifier it rests on. We report what the record states; we do not assert efficacy, and computational findings are pending wet-lab confirmation.
Absence is not evidence of absence: unregistered, non-US and stealth-stage programs are not visible to these sources.
This page refreshes monthly (no net-new primary entity in 74 days). Mechanism classifications are our reading of the public record and may be revised.

Want the analysis behind this landscape?

The public page is the map. The full dossier adds differentiation analysis, kill-tests and the whitespace read for this target — the parts we do not publish.

Request the full dossier All landscapes